Stabilized MetA decreases the frequencies of persisters in different <i>E. coli</i> strains at elevated temperature. by Elena A. Mordukhova (646403)

Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1^fl/fl</i> heart. by Craig Bolte (299486)

“…Numbers of capillaries were counted in PECAM-stained hearts using 10 random sections and mean±SEM was determined to confirm decreased capillary density (I). …”

Expression of IR21a, IR93a, and IR25a proteins decreases in DOCCs at the late third instar. by Jordan J. Tyrrell (10535989)

“…Right: <i>Ir21a>GFP-</i>labeled DOCCs express IR21a (Fig 4A), IR93a (Fig 4C) and IR25a (Fig 4E) proteins at 72 hr AEL (top), which are significantly decreased at 120 hr AEL (bottom). …”

Knockdown of MRPL28 results in a dose-dependent decrease in mitochondrial function. by Yijun Chen (107514)

Rodents engineered with CHIP-T246M had decreased expression of CHIP in the brain and testes, Purkinje cell degeneration, increased mortality, and selective tissue atrophy. by Chang-he Shi (5315918)

Simultaneous ablation of Syt1 and Syt7 decreases the RRP size at inhibitory synapses: Rescue by WT but not mutant Syt1 or Syt7. by Taulant Bacaj (803415)

“…Recordings were performed in the presence of 1 μM tetrodotoxin, 20 μM CNQX, and 50 μM AP5 to isolate inhibitory currents. <b>B.</b> Simultaneous ablation of Syt1 and Syt7 decreases the RRP size of inhibitory synapses in a manner that is rescued by WT Syt7 (Syt1^WT) but not Syt7 with mutations in the top C2 domain sequences containing the Syt7 Ca²⁺ binding sites (Syt7^C2A*^B*). …”

MiR-16 decreases protein expression of VPS4a. by Neeta Adhikari (474583)

“…<p>VPS4a protein is decreased following overexpression of miR-16. …”

CD14^dimCD16+ cells were at decreased frequency in fresh PBMCs of both BeS-NS and CBD. by Li Li (14993)

TGF-β1 had little effect on MMP-2, MMP-3 and MMP-14 expression, but decreased expression of MMP-16. by Youssef M. Farhat (295089)

Cre-mediated activation of RIαB allele specifically in the liver decreases PKA activity in vivo. by Brandon S. Willis (353418)

3D interactions between the ligand and the protein_DNA complex in the first (C1) and second (C2) clusters. by Ahmed A. Gaber (13302308)

Subjects:

Binding of amsacrine with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The center of mass distances between the protein-DNA complex and the ligand (Blue line), and the protein and DNA (red line). by Ahmed A. Gaber (13302308)

Subjects:

Fig 12 - by Ahmed A. Gaber (13302308)

Subjects:

The number of clusters, number of interactions, and their types between the ligand and protein_DNA complex. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 17 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

Fig 4 - by Ahmed A. Gaber (13302308)

Subjects:

Some reported DNA intercalators and their basic pharmacophoric features. by Ahmed A. Gaber (13302308)

Subjects:

The contributions from the different energy components of MM-GBSA. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 19 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects: